

Stefano Caruso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5420038/publications.pdf>

Version: 2024-02-01

65
papers

2,761
citations

172386
29
h-index

197736
49
g-index

68
all docs

68
docs citations

68
times ranked

4661
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 616-626.	6.1	106
2	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , 2022, 76, 343-352.	1.8	30
3	TGF β -induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. <i>Hepatology Communications</i> , 2022, 6, 1157-1171.	2.0	9
4	Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 540-551.	3.2	23
5	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	5.1	36
6	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. <i>Journal of Hepatology</i> , 2022, 77, 116-127.	1.8	40
7	Deleting the β -catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. <i>Journal of Hepatology</i> , 2022, 77, 424-435.	1.8	17
8	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	5.1	66
9	LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways. <i>Liver Cancer</i> , 2022, 11, 126-140.	4.2	3
10	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. <i>Hepatology</i> , 2021, 73, 14-26.	3.6	66
11	The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 127-139.	2.6	21
12	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	1.8	54
13	The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD. <i>Cancers</i> , 2021, 13, 411.	1.7	28
14	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1554.	1.7	9
15	AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G543-G556.	1.6	5
16	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021, 11, 2524-2543.	7.7	41
17	Expression of NKG2D ligands is downregulated by β -catenin signalling and associates with HCC aggressiveness. <i>Journal of Hepatology</i> , 2021, 74, 1386-1397.	1.8	37
18	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021, 13, 113.	3.6	31

#	ARTICLE	IF	CITATIONS
19	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	0.9	9
20	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 4910-4925.	0.4	30
21	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021, 74, 816-834.	3.6	20
22	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	0.8	12
23	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129
24	Polyploidy spectrum: a new marker in HCC classification. <i>Gut</i> , 2020, 69, 355-364.	6.1	82
25	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020, 69, 737-747.	6.1	78
26	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	6.1	17
27	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	1.8	44
28	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ER α and HNF1 α . <i>Cancers</i> , 2020, 12, 2213.	1.7	4
29	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020, 15, e0238809.	1.1	5
30	Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, e113-e116.	0.5	2
31	Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. <i>Molecular Oncology</i> , 2020, 14, 1207-1223.	2.1	74
32	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 160-178.	3.6	36
33	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	3.6	81
34	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 5859-5865.	3.2	64
35	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e909-e912.	0.9	1
36	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141

#	ARTICLE	IF	CITATIONS
37	THU-456-Polyploidy spectrum: a new marker of molecular HCC tumour classification. Journal of Hepatology, 2019, 70, e360.	1.8	0
38	THU-374-The lncRNA H19-derived MIR-675 promotes liver necroptosis by targeting fadd. Journal of Hepatology, 2019, 70, e318.	1.8	0
39	THU-445-Beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis. Journal of Hepatology, 2019, 70, e354-e355.	1.8	0
40	FRI-465-The lncRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model. Journal of Hepatology, 2019, 70, e601-e602.	1.8	0
41	THU-452-TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e357-e358.	1.8	0
42	A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma. Gastroenterology, 2019, 157, 1477-1479.	0.6	8
43	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	0.9	34
44	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332.	1.8	11
45	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology, 2019, 8, e1583547.	2.1	31
46	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology, 2018, 68, 964-976.	3.6	43
47	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. Gastroenterology, 2018, 155, 1951-1966.e26.	0.6	86
48	Palmitoylation is a post-translational modification of Alix regulating the membrane organization of exosome-like small extracellular vesicles. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2879-2887.	1.1	42
49	Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 2018, 33, 1061-1077.e6.	7.7	151
50	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 2017, 66, 734-742.	1.8	31
51	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
52	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. PPAR Research, 2017, 2017, 1-15.	1.1	119
53	The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer. PPAR Research, 2017, 2017, 1-2.	1.1	55
54	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget, 2016, 7, 47821-47830.	0.8	36

#	ARTICLE	IF	CITATIONS
55	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321.	2.0	30
56	Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 475-485.	0.9	54
57	Abstract 448: Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: Feasibility study. , 2014, , .		0
58	Effects of PPAR α agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2013, 228, 1368-1374.	2.0	29
59	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	1.1	29
60	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1249-1261.	1.5	41
61	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	32
62	High density of tryptase α -positive mast cells in human colorectal cancer: a poor prognostic factor related to protease α -activated receptor 2 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1025-1037.	1.6	80
63	MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, 04, .	0.3	3
64	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. <i>Oncogenesis</i> , 2012, 1, e32-e32.	2.1	45
65	Analysis of molecular mechanisms and anti α -tumoural effects of zoledronic acid in breast cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2186-2195.	1.6	23